Corcept Q1 revenue up 39% to $146.8M; raises FY2024 guidance to $620-650M

CORCEPT THERAPEUTICS INC

2024-Q1 EPS reported $0.25 revenue$146,808,000

Revenue $146.8M (+39% YoY); diluted EPS $0.25 vs $0.14; net income $27.8M.
2024 revenue guidance raised to $620-650M from $600-630M.
Cash and investments $451.0M at March 31, 2024.
GRACE open-label phase showed significant improvements; NDA for relacorilant in Cushing's expected this quarter.
Enrollment completed in GRADIENT, CATALYST, ROSELLA, DAZALS; data expected by year-end.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.